Page 318 - AIDSBK23C
P. 318

Page 318




               251     Khalsa AM. Preventive counseling, screening, and therapy for the patient with newly
                       diagnosed HIV infection. Am Fam Physician. 2006;73:271-280.

               252     Holtgrave D. Evidence-based efforts to prevent HIV infection: an overview of current
                       status and future challenges. Clin Infect Dis. 2007;45 Suppl 4:S293-299.

               253     Yarchoan R, Mitsuya H, Broder S. AIDS therapies. Sci Am. 1988;259:110-119.

               254     Warnke D, Barreto J, Temesgen Z. Antiretroviral drugs. J Clin Pharmacol.
                       2007;47:1570-1579.

               255     Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl
                       J Med. 1993;328:1686-1695.

               256     Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM,
                       Günthard HF, et al; International AIDS Society-USA. Antiretroviral treatment of adult
                       HIV infection: 2010 recommendations of the International AIDS Society-USA panel.
                       JAMA. 2010;304:321-333..

               257     Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic
                       Kidney Dis. 2010;17:72-82.

               258     Vivet-Boudou V, Didierjean J, Isel C, Marquet R. Nucleoside and nucleotide inhibitors of
                       HIV-1 replication. Cell Mol Life Sci. 2006;63:163-186.

               259     Arenas-Pinto A, Grant AD, Edwards S, Weller IV. Lactic acidosis in HIV infected
                       patients: a systematic review of published cases. Sex Transm Infect. 2003;79:340-343.

               260     Neuman MG, Schneider M, Nanau RM, Parry C. HIV-Antiretroviral Therapy Induced
                       Liver, Gastrointestinal, and Pancreatic Injury. Int J Hepatol. 2012;2012:760706.

               261     Hoetelmans RM. Pharmacology of antiretroviral drugs. Antiviral Ther. 1999;4 Suppl
                       3:29-41.

               262     Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions
                       associated with the use of human immunodeficiency virus medications. Acta Derm
                       Venereol. 2003;83:1-9.


               263     Adams J, Patel N, Mankaryous N, Tadros M, Miller CD. Nonnucleoside reverse
                       transcriptase inhibitor resistance and the role of the second-generation agents. Ann
                       Pharmacother. 2010;44:157-165.

               264     McDonald SK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors.
                       Arch Intern Med. 1997;157:951-959.
   313   314   315   316   317   318   319   320   321   322   323